<?xml version="1.0" encoding="UTF-8"?>
<p>In December 2014, the Innovative Medicines Initiative awarded funding from the Ebola + programme to the EBOVAC1 consortium of research institutions in partnership with the Janssen Pharmaceutical Companies of Johnson &amp; Johnson (Janssen) to support the development and evaluation of a prime-boost prophylactic Ebola vaccine regimen.
 <sup>
  <xref rid="bibr2-1740774518780678" ref-type="bibr">2</xref>,
  <xref rid="bibr3-1740774518780678" ref-type="bibr">3</xref>
 </sup> The EBOVAC-Salone study in Sierra Leone, which is still ongoing, is part of the EBOVAC1 project.
</p>
